Sec Form 4 Filing - Betz Stephen F. @ Crinetics Pharmaceuticals, Inc. - 2026-09-01

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Betz Stephen F. 2. Issuer Name and Ticker or Trading Symbol Crinetics Pharmaceuticals, Inc. [ CRNX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Scientific Officer (Last) (First) (Middle) C/O CRINETICS PHARMACEUTICALS, INC., 6055 LUSK BOULEVARD 3. Date of Earliest Transaction (MM/DD/YY) 09/01/2026 (Street) SAN DIEGO, CA92121 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 09/01/2026 D 58,286 ( 1 ) D $ 85 ( 2 ) 79,650 D Common Stock 09/01/2026 D 79,650 D $ 85 ( 3 ) 0 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy) $ 1.91 09/01/2026 D 90,514 ( 4 )( 5 ) 03/16/2028 Common Stock 90,514 $ 83.09 ( 4 ) ( 5 ) 0 D Stock Option (Right to Buy) $ 9.28 09/01/2026 D 74,540 ( 4 )( 5 ) 05/24/2028 Common Stock 74,540 $ 75.72 ( 4 ) ( 5 ) 0 D Stock Option (Right to Buy) $ 25.19 09/01/2026 D 56,250 ( 4 )( 5 ) 03/08/2029 Common Stock 56,250 $ 59.81 ( 4 ) ( 5 ) 0 D Stock Option (Right to Buy) $ 22.61 09/01/2026 D 60,000 ( 4 )( 5 ) 02/24/2030 Common Stock 60,000 $ 62.39 ( 4 ) ( 5 ) 0 D Stock Option (Right to Buy) $ 15.29 09/01/2026 D 85,000 ( 4 )( 5 ) 02/26/2031 Common Stock 85,000 $ 69.71 ( 4 ) ( 5 ) 0 D Stock Option (Right to Buy) $ 23.19 09/01/2026 D 15,000 ( 4 )( 5 ) 09/10/2031 Common Stock 15,000 $ 61.81 ( 4 ) ( 5 ) 0 D Stock Option (Right to Buy) $ 20.02 09/01/2026 D 77,000 ( 4 )( 5 ) 02/29/2032 Common Stock 77,000 $ 64.98 ( 4 ) ( 5 ) 0 D Stock Option (Right to Buy) $ 19.64 09/01/2026 D 110,000 ( 4 )( 5 ) 02/28/2033 Common Stock 110,000 $ 65.36 ( 4 ) ( 5 ) 0 D Stock Option (Right to Buy) $ 43.51 09/01/2026 D 87,000 ( 4 )( 5 ) 03/03/2034 Common Stock 87,000 $ 41.49 ( 4 ) ( 5 ) 0 D Stock Option (Right to Buy) $ 36.86 09/01/2026 D 65,000 ( 4 )( 5 ) 02/19/2035 Common Stock 65,000 $ 48.14 ( 4 ) ( 5 ) 0 D Stock Option (Right to Buy) $ 43.79 09/01/2026 D 47,000 ( 4 )( 5 ) 02/23/2036 Common Stock 47,000 $ 41.21 ( 4 ) ( 5 ) 0 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Betz Stephen F. C/O CRINETICS PHARMACEUTICALS, INC. 6055 LUSK BOULEVARD SAN DIEGO, CA92121 Chief Scientific Officer Signatures /s/ Tobin Schilke, as attorney-in-fact 09/01/2026 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Includes 835 shares acquired under the Issuer's Employee Stock Purchase Plan. ( 2 )Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). ( 3 )The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding. ( 4 )The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. ( 5 )The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.